IOVA Earnings Date: Nov 5, 2026 (Estimated) — Iovance Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is IOVA's next earnings date?
Iovance Biotherapeutics, Inc. (IOVA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.08 on revenue of $115.5M.
How did IOVA do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Iovance Biotherapeutics, Inc. posted EPS of -$0.11 versus the -$0.13 estimate, a beat of 21.4%. Revenue was $99.3M against a $87.8M estimate. The stock's 1-day post-earnings move was +43.1%.
How much does IOVA stock move after earnings?
IOVA beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 26.6% (up or down) in the day after earnings.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.13 | -0.11 | +21.43% | $99.3M | ✅ Beat | +43.09% | +55.30% | +100.46% |
| 2026-05-07 | Q1 2026 | -0.16 | -0.19 | -18.75% | $71.4M | ❌ Miss | -13.20% | -10.51% | +3.42% |
| 2026-02-24 | Q4 2025 | -0.19 | -0.18 | +5.26% | $86.8M | ✅ Beat | +30.80% | +31.14% | +25.26% |
| 2025-11-06 | Q3 2025 | -0.27 | -0.25 | +7.41% | $67.5M | ✅ Beat | +27.62% | +40.33% | +21.55% |
| 2025-08-07 | Q2 2025 | -0.28 | -0.33 | -17.86% | $60.0M | ❌ Miss | -20.08% | -7.20% | -9.85% |
| 2025-05-08 | Q1 2025 | -0.24 | -0.36 | -50.00% | $49.3M | ❌ Miss | -44.80% | -44.48% | -30.28% |
| 2025-02-27 | Q4 2024 | -0.27 | -0.26 | +3.70% | $73.7M | ✅ Beat | -19.49% | -28.71% | -32.32% |
| 2024-11-07 | Q3 2024 | -0.30 | -0.28 | +6.67% | $58.6M | ✅ Beat | -13.80% | -30.05% | -27.20% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $99.3M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.7% | $99.0M | +68.9% | $103.2M | $48.5M | $58.6M | $66.4M |
| Non-US | 0.3% | $346K | -74.3% | $1.6M | $804K | $1.3M | $1.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.